Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial


Hulin C, Belch A, Shustik C, Petrucci MT, Dührsen U, Lu J, Song K, Rodon P, Pégourié B, Garderet L, et al. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial. Journal of Clinical Oncology [Internet]. 2016;34(30):3609 - 3617.


Purpose: This analysis of the FIRST trial in patients with newly diagnosed multiple myeloma (MM) ineligible for stem-cell transplantation examined updated outcomes and impact of patient age. Patients and Methods: Patients with untreated symptomatic MM were randomly assigned at a one-to-one-to-one ratio to lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous), Rd for 72 weeks (18 cycles; Rd18), or melphalan, prednisone, and thalidomide (MPT; 72 weeks), stratified by age (≤ 75 v > 75 years), disease stage (International Staging System stage I/II v III), and country. The primary end point was progression-free survival. Rd continuous and MPT were primary comparators. Results: Between August 21, 2008, and March 7, 2011, 1,623 patients were enrolled (Rd continuous, n = 535; Rd18, n = 541; MPT, n = 547), including 567 (35%) age older than 75 years. Higher rates of advanced-stage disease and renal impairment were observed in patients older than 75 versus 75 years of age or younger. Rd continuous reduced the risk of progression or death compared with MPT by 31% (hazard ratio [HR], 0.69; 95% CI, 0.59 to 0.80; P <.001) overall, 36% (HR, 0.64; 95% CI, 0.53 to 0.77; P <.001) in patients age 75 years or younger, and 20% (HR, 0.80; 95% CI, 0.62 to 1.03; P =.084) in those age older than 75 years. Median overall survival was longer with Rd continuous than with MPT, including a 14-month difference in patients age older than 75 years. Progression-free survival with Rd18 was similar to that with MPT, and overall survival with Rd18 was marginally inferior to that with Rd continuous. Rates of grade 3 to 4 treatment-emergent adverse events were similar for Rd continuous-treated patients age 75 years or older and those age older than 75 years; however, older patients had more frequent lenalidomide dose reductions. Conclusion: Results support Rd continuous treatment as a new standard of care for stem-cell transplantation-ineligible patients with newly diagnosed MM of all ages. © 2016 by American Society of Clinical Oncology.


Cited By :2Export Date: 18 February 2017References: Turesson, I., Velez, R., Kristinsson, S.Y., Patterns of multiple myeloma during the past 5 decades: Stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic (2010) Mayo Clin Proc, 85, pp. 225-230;Howlader, N., Noone, A.M., Krapcho, M., SEER Cancer Statistics Review, 1975-2011., , http://seer.cancer.gov/csr/1975_2011; Sant, M., Minicozzi, P., Mounier, M., Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: Results of EUROCARE-5, a population-based study (2014) Lancet Oncol, 15, pp. 931-942; Wildes, T.M., Rosko, A., Tuchman, S.A., Multiple myeloma in the older adult: Better prospects, more challenges (2014) J Clin Oncol, 32, pp. 2531-2540; Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients (2014) Leukemia, 28, pp. 1122-1128; Schaapveld, M., Visser, O., Siesling, S., Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989 (2010) Eur J Cancer, 46, pp. 160-169; Pozzi, S., Marcheselli, L., Bari, A., Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: A population-based analysis (2013) Br J Haematol, 163, pp. 40-46; Zweegman, S., Palumbo, A., Bringhen, S., Age and aging in blood disorders: Multiple myeloma (2014) Haematologica, 99, pp. 1133-1137; Palumbo, A., Mina, R., Management of older adults with multiple myeloma (2013) Blood Rev, 27, pp. 133-142; Palumbo, A., Bringhen, S., Ludwig, H., Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN) (2011) Blood, 118, pp. 4519-4529; Fayers, P.M., Palumbo, A., Hulin, C., Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials (2011) Blood, 118, pp. 1239-1247; Moreau, P., Hulin, C., Facon, T., Frontline therapy for patients with multiple myeloma not eligible for stem cell transplantation (2014) Hematol Oncol Clin North Am, 28, pp. 829-838; Facon, T., Mary, J.Y., Hulin, C., Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial (2007) Lancet, 370, pp. 1209-1218; Waage, A., Gimsing, P., Fayers, P., Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma (2010) Blood, 116, pp. 1405-1412; (2015) Revlimid (lenalidomide) Package insert., , Summit, NJ, Celgene; (2015) Revlimid (lenalidomide) Summary of Product characteristics., , Uxbridge, United Kingdom, Celgene Europe Limited; Benboubker, L., Dimopoulos, M.A., Dispenzieri, A., Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma (2014) N Engl J Med, 371, pp. 906-917; Delforge, M., Minuk, L., Eisenmann, J.C., Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: Lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide (2015) Haematologica, 100, pp. 826-833; Durie, B.G.M., Harousseau, J.L., Miguel, J.S., International uniform response criteria for multiple myeloma (2006) Leukemia, 20, pp. 1467-1473; DeMets, D.L., Lan, K.K., Interim analysis: The alpha spending function approach (1994) Stat Med, 13, pp. 1341-1352. , discussion 1353-1356; Pocock, S.J., Interim analyses for randomized clinical trials: The group sequential approach (1982) Biometrics, 38, pp. 153-162; Palumbo, A., Rajkumar, S.V., San Miguel, J.F., International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation (2014) J Clin Oncol, 32, pp. 587-600; Cherubini, A., Pierri, F., Gasperini, B., Are ongoing trials on hematologic malignancies still excluding older subjects? (2013) Haematologica, 98, pp. 997-1000; Palumbo, A., Bringhen, S., Mateos, M.V., Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report (2015) Blood, 125, pp. 2068-2074; Facon, T., San Miguel, J., Mateos, M.V., Frontline treatment in elderly patients with multiple myeloma (2009) Semin Hematol, 46, pp. 133-142; Hulin, C., Facon, T., Rodon, P., Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial (2009) J Clin Oncol, 27, pp. 3664-3670; Palumbo, A., Waage, A., Hulin, C., Safety of thalidomide in newly diagnosed elderly myeloma patients: A meta-analysis of data from individual patients in six randomized trials (2013) Haematologica, 98, pp. 87-94; Liwing, J., Uttervall, K., Lund, J., Improved survival in myeloma patients: Starting to close in on the gap between elderly patients and a matched normal population (2014) Br J Haematol, 164, pp. 684-693